Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181026 | 1.00 | MEN1 (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL680551 | 1.00 | MEN1 (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL17343612 | 1.00 | MEN1 (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL30272955 | 0.96 | MEN1 (0.35) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL30272956 | 0.76 | CYP1A2 (0.38) | MEN1KMT2A | |
| SCHEMBL5111850 | 0.75 | MEN1 (0.33) | MEN1GAAKMT2AHTR2A | |
| SCHEMBL30424597 | 0.74 | HTR2A (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL8531996 | 0.74 | MAOA (0.38) | MEN1GAAKMT2AHTR2A | |
| SCHEMBL24475199 | 0.73 | MEN1 (0.33) | MEN1GAAKMT2AHTR2A | |
| SCHEMBL6237164 | 0.73 | MEN1 (0.33) | MEN1GAAKMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| CN-113975274-A | Cyclofused thiazoline 2-pyridones, method for the production thereof and use thereof for treating and/or preventing tuberculosis | 快尔生物技术公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-109069492-B | Cyclofused thiazoline 2-pyridones, method for the production thereof and use thereof for treating and/or preventing tuberculosis | 快尔生物技术公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-107961215-B | Levocetirizine injection | 北京科信必成医药科技发展有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-107961214-B | Cetirizine injection | 北京科信必成医药科技发展有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-112105624-A | Treatment of cancer using (2, 2-bis hydroxymethyl) methylene cyclopropane nucleotides | 美迪维尔公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| CN-111246848-A | Cyclofused thiazolo 2-pyridones in combination with antitubercular agents | 快尔生物技术公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-110799513-A | Ring-fused thiazolo-2-pyridones, method for the production thereof and use thereof for treating and/or preventing diseases which involve gram-positive bacteria | 快尔生物技术公司 | 2020-02-14 | — | — | CN | disclosed |
| CN-107074878-B | 2, 3-dihydro-thiazolo [3,2-a ] pyridin-5-one derivatives, intermediates thereof and their use as antibacterial agents | 快尔生物技术公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20110004164-A1 | NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF | ESTEVE PHARMACEUTICALS S.A. (ES) | 2011-01-06 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20090029945-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20080319017-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080139616-A1 | Atherosclerosis; inflammatory diseases, Alzheimer's disease, dyslipidemia, metabolic syndrome; 2-isopropyl-5-phenyl-4-[(4-phenylbutyl)amino]isothiazole-3(2H)-thione 1,1-dioxide for example | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| US-20080125396-A1 | Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators | ATRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125396-A1 | Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4391/4885GAA 3174/4885KMT2A 3218/4885 |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | MEN1 3713/4885GAA 3700/4885KMT2A 1079/4885 |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4332/4885GAA 2135/4885KMT2A 2880/4885 |
| US-20080319017-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4395/4885GAA 2805/4885KMT2A 3100/4885 |
| US-20080139616-A1 | Atherosclerosis; inflammatory diseases, Alzheimer's disease, dyslipidemia, metabolic syndrome; 2-isopropyl-5-phenyl-4-[(4-phenylbutyl)amino]isothiazole-3(2H)-thione 1,1-dioxide for example | NR1H2, NR1H3, SREBF1 | MEN1 4650/4885GAA 2556/4885KMT2A 3177/4885 |
| US-20090029945-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4395/4885GAA 2805/4885KMT2A 3100/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4332/4885GAA 2135/4885KMT2A 2880/4885 |
| US-20110004164-A1 | NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF | HRH1, HRH2, HRH4 | MEN1 3900/4885GAA 1598/4885KMT2A 350/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4112/4885GAA 2454/4885KMT2A 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.